Latest news with #diagnosticTools
Washington Post
2 days ago
- Health
- Washington Post
How AI could transform the future of medicine
Artificial intelligence is revolutionizing medicine with new diagnostic tools, automated processes and predictive analytics. On Tuesday, Sept. 9 at 9:00 a.m. ET, join Washington Post Live for conversations with prominent leaders in tech and health care about how assistive AI could shape the future of medicine. Amir Dan Rubin CEO & Founding Manager Partner, Healthier Capital Rep. Ami Bera (D-Calif.) Sharmila Makhija Founding Dean & CEO, Alice L. Walton School of Medicine Reid Conant Senior Physician Executive, Abridge Matt MacVey Executive Vice President & Chief Information Officer, Children's National The following content is produced and paid for by a Washington Post Live event sponsor. The Washington Post newsroom is not involved in the production of this content. Christopher Myers Director, Center for Innovative Leadership Professor of Management & Organization, Johns Hopkins Carey Business School Tinglong Dai Professor of Business, Johns Hopkins Carey Business School
Yahoo
10-05-2025
- Business
- Yahoo
HIV Diagnostics Market Projected to Hit USD 1.80 Billion by 2032, Driven by Rising Global Testing Rates and Technological Advancements
Increasing awareness, improved healthcare access, and next-gen diagnostic tools fuel steady 5.10% CAGR growth in the HIV diagnostics market through 2032. Austin, May 10, 2025 (GLOBE NEWSWIRE) -- HIV Diagnostics Market Size Analysis: According to SNS Insider, the HIV Diagnostics Market was valued at USD 1.15 billion in 2023 and is set to reach USD 1.80 billion by 2032, growing at a CAGR of 5.10% during the forecast period of 2024–2032 The need for more rapid and readily accessible diagnostic tests has significantly increased as the global HIV count continues to rise. Advances in technology, improved healthcare facilities, and an increased focus on early diagnosis and prevention are largely responsible for this growth. As public support for healthcare grows, the market for HIV diagnostics will evolve substantially in most nations, especially in Asia-Pacific and North a Sample Report of HIV Diagnostics Market@ The U.S. HIV diagnostics market was valued at USD 0.20 billion in 2023 and is expected to reach USD 0.27 billion by the year 2032. This reflects a 3.36% CAGR. Increased diagnosis rates of HIV, increased awareness, and the embrace of improved diagnostic technology are largely to be blamed for this phenomenon. Innovations like in-home HIV diagnostic kits and point-of-care testing facilities keep the United States' market ahead of others in this regard. Major Players Analysis Listed in this Report are: Alere Inc.: Determine HIV-1/2 Ag/Ab Combo Abbott: ARCHITECT HIV Ag/Ab Combo Assay Bristol-Myers Squibb Company: Sustiva (efavirenz) Janssen Global Services, LLC: Prezista (darunavir) Gilead Sciences, Inc.: Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide), Sunlenca (lenacapavir) Merck & Co., Inc.: Isentress (raltegravir) ViiV Healthcare: Tivicay (dolutegravir), Triumeq (abacavir/dolutegravir/lamivudine) BD (Becton, Dickinson and Company): BD FACSPresto System Beckman Coulter, Inc.: Access HIV Combo Assay PointCare: PointCare NOW System F. Hoffmann-La Roche Ltd.: COBAS AmpliPrep/COBAS TaqMan HIV-1 Test Siemens Healthcare GmbH: ADVIA Centaur HIV Ag/Ab Combo Assay QIAGEN: artus HIV-1 QS-RGQ Kit OraSure Technologies: OraQuick In-Home HIV Test DiaSorin: LIAISON XL murex HIV Ab/Ag HIV Diagnostics Market Report Scope Report Attributes Details Market Size in 2023 US$ 1.15 billion Market Size by 2032 US$ 1.80 billion CAGR CAGR of 5.10% From 2024 to 2032 Base Year 2023 Forecast Period 2024-2032 Historical Data 2020-2022 Key Regional Coverage North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East]), Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) Segment Analysis By Product: Comprising a market share of 45.5%, the consumables sector led the HIV diagnostics market in 2023. The great demand for consumable items, reagents, and diagnostic kits used in HIV testing accounts for the predominance of this category. Consumables remain the main source of income, even with the rising number of diagnostic treatments carried out. Conversely, the sector of software and services is predicted to increase the most since the increasing acceptance of digital platforms and AI-based diagnostic tools enhances patient management and testing accuracy, thereby improving the segment. By Mode: With 90.9% of the market share in 2023, the category of laboratory-based testing kept its leading place. Given that laboratory-based tests—which are regarded as the gold standard for HIV diagnosis—have great accuracy and dependability, their supremacy results mostly from their On the other hand, the segment of self-testing is predicted to rise most since need for privacy and convenience lets people test for HIV in the comfort of their homes. The broad availability of at-home testing kits and a move toward decentralization in healthcare services promote this trend. By Test Type: With a 53.6% share of income, the segment of the antibody tests dominated the test category in 2023. The most often used HIV diagnostic test, the antibody tests, are the reason behind this supremacy since they produce consistent and accurate findings in HIV infection detection. Given its rising use in both clinical environments and at-home testing options, where it is considered the first line of HIV detection, the antibody test segment is also expected to increase the most. By End Use: The biggest end-use category in the HIV diagnostics market, the diagnostic labs segment, produced 50.4% of market revenue in 2023. HIV testing is mostly dependent on diagnostic labs since they can offer accurate, high-throughput testing. Driven by the growing availability and simplicity of home testing kits, the sector in home settings is predicted to develop fastest. In areas with high HIV prevalence and restricted access to healthcare infrastructure, this trend is especially noteworthy. For A Detailed Briefing Session with Our Team of Analysts, Connect with Us Now@ HIV Diagnostics Market Segmentation By Product Consumables Instruments Software and Services By Mode Self-test Lab-based By Test type Antibody Test HIV-1 Screening Tests HIV-1 Antibody Confirmatory Tests HIV-2 & Group O Diagnostic Tests Viral load test CD4 test Others By End Use Diagnostic Laboratories Hospitals & Clinics Home Settings Recent Developments in HIV Diagnostics In November 2024, Egypt and the Global Fund signed a Framework Agreement aimed at strengthening health systems and improving HIV and tuberculosis response efforts while addressing the ongoing impact of COVID-19. UNDP will coordinate efforts with the Ministry of Health and civil society organizations to enhance HIV prevention and diagnostic services. In April 2024, Cepheid received WHO prequalification for its Xpert HIV-1 Qual XC test. This point-of-care diagnostic test enables early HIV detection in infants using dried blood spots and whole blood samples, thus enhancing accessibility and accuracy in HIV diagnostics, especially in resource-limited settings. In January 2024, Abbott launched the ARCHITECT HIV Ag/Ab Combo test, which provides reliable and rapid detection of HIV infection by identifying both HIV antibodies and antigens. This test aims to improve diagnostic accuracy and accelerate HIV detection in clinical settings. In March 2024, Mylan announced the launch of its generic HIV self-testing kit, which is designed to provide users with a simple, accurate, and confidential method to test for HIV at home. The launch is part of Mylan's broader effort to improve access to affordable HIV diagnostics globally. In February 2024, Roche introduced a new fully automated system for HIV diagnostics, combining antigen and antibody testing for faster and more accurate results. This innovation is expected to improve efficiency in high-throughput testing labs. Regional Analysis North America dominated the HIV diagnostics market in 2023 due to the presence of leading healthcare providers and the high demand for advanced diagnostic solutions. Government initiatives, such as increased funding for HIV awareness and testing programs, have contributed to the market's dominance in the region. Furthermore, the region's well-established healthcare infrastructure and adoption of cutting-edge diagnostic technologies, including self-testing kits and at-home diagnostic tools, continue to drive market growth. Asia Pacific is expected to experience the highest growth from 2024 to 2032. The region has a large HIV-infected population, and increasing government and private sector efforts to combat the disease. Growing awareness, improved access to healthcare services, and the increasing adoption of advanced HIV diagnostics are driving this rapid growth. Statistical Insights and Trends Reporting In 2023, the global incidence of new HIV cases was approximately 1.5 million, with Sub-Saharan Africa accounting for the majority of new infections. North America accounted for the highest share of HIV testing prescriptions, with a growing shift toward self-testing and rapid diagnostic tests. North America and Europe dominated the HIV diagnostics device volume in 2023, while Asia Pacific is expected to show the highest volume growth due to increased testing and awareness. In 2023, government-funded HIV diagnostic programs accounted for 60% of global HIV testing efforts, with the remaining share split between commercial healthcare providers and out-of-pocket expenditures in low-income a Single-User PDF of HIV Diagnostics Market Analysis & Outlook Report 2024-2032@ Table of Contents – Major Key Points 1. Introduction 2. Executive Summary 3. Research Methodology 4. Market Dynamics Impact Analysis 5. Statistical Insights and Trends Reporting 5.1 Incidence and Prevalence of HIV (2023) 5.2 HIV Testing and Diagnosis Rates (2023), by Region 5.3 HIV Diagnostic Test Volume, by Region (2020-2032) 5.4 Healthcare Spending on HIV Diagnostics, by Region (Government, Commercial, Private, Out-of-Pocket), 2023 5.5 Adoption of Advanced HIV Diagnostic Technologies (2023-2032) 5.6 Regulatory Approvals and Policy Impact on HIV Diagnostics (2023-2032) 6. Competitive Landscape 7. HIV Diagnostics Market by Product 8. HIV Diagnostics Market by Mode 9. HIV Diagnostics Market by Test type 10. HIV Diagnostics Market by End Use 11. Regional Analysis 12. Company Profiles 13. Use Cases and Best Practices 14. Conclusion Related Reports: Point-of-Care Testing Market Analysis Molecular Diagnostics Market Forecast Immunoassay Analyzers Market Trends STD Diagnostics Market Outlook Rapid Medical Diagnostic Kits Market Overview About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world. CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10-05-2025
- Business
- Yahoo
HIV Diagnostics Market Projected to Hit USD 1.80 Billion by 2032, Driven by Rising Global Testing Rates and Technological Advancements
Increasing awareness, improved healthcare access, and next-gen diagnostic tools fuel steady 5.10% CAGR growth in the HIV diagnostics market through 2032. Austin, May 10, 2025 (GLOBE NEWSWIRE) -- HIV Diagnostics Market Size Analysis: According to SNS Insider, the HIV Diagnostics Market was valued at USD 1.15 billion in 2023 and is set to reach USD 1.80 billion by 2032, growing at a CAGR of 5.10% during the forecast period of 2024–2032 The need for more rapid and readily accessible diagnostic tests has significantly increased as the global HIV count continues to rise. Advances in technology, improved healthcare facilities, and an increased focus on early diagnosis and prevention are largely responsible for this growth. As public support for healthcare grows, the market for HIV diagnostics will evolve substantially in most nations, especially in Asia-Pacific and North a Sample Report of HIV Diagnostics Market@ The U.S. HIV diagnostics market was valued at USD 0.20 billion in 2023 and is expected to reach USD 0.27 billion by the year 2032. This reflects a 3.36% CAGR. Increased diagnosis rates of HIV, increased awareness, and the embrace of improved diagnostic technology are largely to be blamed for this phenomenon. Innovations like in-home HIV diagnostic kits and point-of-care testing facilities keep the United States' market ahead of others in this regard. Major Players Analysis Listed in this Report are: Alere Inc.: Determine HIV-1/2 Ag/Ab Combo Abbott: ARCHITECT HIV Ag/Ab Combo Assay Bristol-Myers Squibb Company: Sustiva (efavirenz) Janssen Global Services, LLC: Prezista (darunavir) Gilead Sciences, Inc.: Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide), Sunlenca (lenacapavir) Merck & Co., Inc.: Isentress (raltegravir) ViiV Healthcare: Tivicay (dolutegravir), Triumeq (abacavir/dolutegravir/lamivudine) BD (Becton, Dickinson and Company): BD FACSPresto System Beckman Coulter, Inc.: Access HIV Combo Assay PointCare: PointCare NOW System F. Hoffmann-La Roche Ltd.: COBAS AmpliPrep/COBAS TaqMan HIV-1 Test Siemens Healthcare GmbH: ADVIA Centaur HIV Ag/Ab Combo Assay QIAGEN: artus HIV-1 QS-RGQ Kit OraSure Technologies: OraQuick In-Home HIV Test DiaSorin: LIAISON XL murex HIV Ab/Ag HIV Diagnostics Market Report Scope Report Attributes Details Market Size in 2023 US$ 1.15 billion Market Size by 2032 US$ 1.80 billion CAGR CAGR of 5.10% From 2024 to 2032 Base Year 2023 Forecast Period 2024-2032 Historical Data 2020-2022 Key Regional Coverage North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East]), Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) Segment Analysis By Product: Comprising a market share of 45.5%, the consumables sector led the HIV diagnostics market in 2023. The great demand for consumable items, reagents, and diagnostic kits used in HIV testing accounts for the predominance of this category. Consumables remain the main source of income, even with the rising number of diagnostic treatments carried out. Conversely, the sector of software and services is predicted to increase the most since the increasing acceptance of digital platforms and AI-based diagnostic tools enhances patient management and testing accuracy, thereby improving the segment. By Mode: With 90.9% of the market share in 2023, the category of laboratory-based testing kept its leading place. Given that laboratory-based tests—which are regarded as the gold standard for HIV diagnosis—have great accuracy and dependability, their supremacy results mostly from their On the other hand, the segment of self-testing is predicted to rise most since need for privacy and convenience lets people test for HIV in the comfort of their homes. The broad availability of at-home testing kits and a move toward decentralization in healthcare services promote this trend. By Test Type: With a 53.6% share of income, the segment of the antibody tests dominated the test category in 2023. The most often used HIV diagnostic test, the antibody tests, are the reason behind this supremacy since they produce consistent and accurate findings in HIV infection detection. Given its rising use in both clinical environments and at-home testing options, where it is considered the first line of HIV detection, the antibody test segment is also expected to increase the most. By End Use: The biggest end-use category in the HIV diagnostics market, the diagnostic labs segment, produced 50.4% of market revenue in 2023. HIV testing is mostly dependent on diagnostic labs since they can offer accurate, high-throughput testing. Driven by the growing availability and simplicity of home testing kits, the sector in home settings is predicted to develop fastest. In areas with high HIV prevalence and restricted access to healthcare infrastructure, this trend is especially noteworthy. For A Detailed Briefing Session with Our Team of Analysts, Connect with Us Now@ HIV Diagnostics Market Segmentation By Product Consumables Instruments Software and Services By Mode Self-test Lab-based By Test type Antibody Test HIV-1 Screening Tests HIV-1 Antibody Confirmatory Tests HIV-2 & Group O Diagnostic Tests Viral load test CD4 test Others By End Use Diagnostic Laboratories Hospitals & Clinics Home Settings Recent Developments in HIV Diagnostics In November 2024, Egypt and the Global Fund signed a Framework Agreement aimed at strengthening health systems and improving HIV and tuberculosis response efforts while addressing the ongoing impact of COVID-19. UNDP will coordinate efforts with the Ministry of Health and civil society organizations to enhance HIV prevention and diagnostic services. In April 2024, Cepheid received WHO prequalification for its Xpert HIV-1 Qual XC test. This point-of-care diagnostic test enables early HIV detection in infants using dried blood spots and whole blood samples, thus enhancing accessibility and accuracy in HIV diagnostics, especially in resource-limited settings. In January 2024, Abbott launched the ARCHITECT HIV Ag/Ab Combo test, which provides reliable and rapid detection of HIV infection by identifying both HIV antibodies and antigens. This test aims to improve diagnostic accuracy and accelerate HIV detection in clinical settings. In March 2024, Mylan announced the launch of its generic HIV self-testing kit, which is designed to provide users with a simple, accurate, and confidential method to test for HIV at home. The launch is part of Mylan's broader effort to improve access to affordable HIV diagnostics globally. In February 2024, Roche introduced a new fully automated system for HIV diagnostics, combining antigen and antibody testing for faster and more accurate results. This innovation is expected to improve efficiency in high-throughput testing labs. Regional Analysis North America dominated the HIV diagnostics market in 2023 due to the presence of leading healthcare providers and the high demand for advanced diagnostic solutions. Government initiatives, such as increased funding for HIV awareness and testing programs, have contributed to the market's dominance in the region. Furthermore, the region's well-established healthcare infrastructure and adoption of cutting-edge diagnostic technologies, including self-testing kits and at-home diagnostic tools, continue to drive market growth. Asia Pacific is expected to experience the highest growth from 2024 to 2032. The region has a large HIV-infected population, and increasing government and private sector efforts to combat the disease. Growing awareness, improved access to healthcare services, and the increasing adoption of advanced HIV diagnostics are driving this rapid growth. Statistical Insights and Trends Reporting In 2023, the global incidence of new HIV cases was approximately 1.5 million, with Sub-Saharan Africa accounting for the majority of new infections. North America accounted for the highest share of HIV testing prescriptions, with a growing shift toward self-testing and rapid diagnostic tests. North America and Europe dominated the HIV diagnostics device volume in 2023, while Asia Pacific is expected to show the highest volume growth due to increased testing and awareness. In 2023, government-funded HIV diagnostic programs accounted for 60% of global HIV testing efforts, with the remaining share split between commercial healthcare providers and out-of-pocket expenditures in low-income a Single-User PDF of HIV Diagnostics Market Analysis & Outlook Report 2024-2032@ Table of Contents – Major Key Points 1. Introduction 2. Executive Summary 3. Research Methodology 4. Market Dynamics Impact Analysis 5. Statistical Insights and Trends Reporting 5.1 Incidence and Prevalence of HIV (2023) 5.2 HIV Testing and Diagnosis Rates (2023), by Region 5.3 HIV Diagnostic Test Volume, by Region (2020-2032) 5.4 Healthcare Spending on HIV Diagnostics, by Region (Government, Commercial, Private, Out-of-Pocket), 2023 5.5 Adoption of Advanced HIV Diagnostic Technologies (2023-2032) 5.6 Regulatory Approvals and Policy Impact on HIV Diagnostics (2023-2032) 6. Competitive Landscape 7. HIV Diagnostics Market by Product 8. HIV Diagnostics Market by Mode 9. HIV Diagnostics Market by Test type 10. HIV Diagnostics Market by End Use 11. Regional Analysis 12. Company Profiles 13. Use Cases and Best Practices 14. Conclusion Related Reports: Point-of-Care Testing Market Analysis Molecular Diagnostics Market Forecast Immunoassay Analyzers Market Trends STD Diagnostics Market Outlook Rapid Medical Diagnostic Kits Market Overview About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world. CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
